Latest news with #SVRA
Yahoo
21-05-2025
- Business
- Yahoo
Savara Inc. (SVRA): Analysts See 212% Upside Potential
We recently published an article titled . Savara Inc. (NASDAQ:SVRA) was one of the stocks that was covered in that article. Wall Street analysts believe SVRA has a 212% upside potential over the next 12 months. Close-up of an inhaler, representing the inhalation of the molgramostim product candidate. Savara Inc. (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company dedicated to addressing the unmet needs of patients suffering from rare respiratory diseases. Founded in 1995, Savara is a key player in this niche field through innovative therapeutic development and a commitment to delivering life-changing solutions to patients worldwide. The company focuses on diseases that have limited treatment options, ensuring its research has a significant impact on improving health outcomes. The cornerstone of Savara Inc. (NASDAQ:SVRA) current pipeline is MOLBREEVI, a promising therapeutic designed to treat autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disease characterized by the accumulation of surfactant in the alveoli, impeding gas exchange and leading to respiratory distress. MOLBREEVI is currently undergoing Phase 3 clinical trials and has already demonstrated notable improvements in gas exchange, as well as measurable clinical benefits for patients. Savara is actively pursuing regulatory approval through a rolling Biologics License Application (BLA) submission to the FDA, and it is preparing for a Marketing Authorization Application (MAA) to the European Medicines Agency. These efforts reflect Savara's commitment to bringing MOLBREEVI to market as efficiently as possible. Unlike many biopharmaceutical companies, Savara employs a unique business model that emphasizes outsourcing the majority of its clinical development and manufacturing activities to specialized vendors and consultants. This approach enables the company to operate in a capital-efficient manner, maximizing resources while maintaining the highest standards of quality and innovation. Additionally, Savara's leadership team has extensive experience in navigating the complexities of drug development and commercialization, further strengthening its strategic position in the industry. Financially, Savara Inc. (NASDAQ:SVRA) is in a strong position, with approximately $196 million in cash and short-term investments as of its latest financial report. This robust financial reserve ensures the company's operations remain funded through Q2 2027, providing a solid foundation for advancing its pipeline and achieving its goals. Analysts have expressed optimism about Savara's prospects, citing the company's growing momentum, innovative pipeline, and prudent investment strategy as key drivers of its twelve-month average price target of $9.44, which reflects a substantial upside potential of 212.84%. Overall, Savara Inc. (NASDAQ:SVRA) ranks 13th on our list of 13 Best Multibagger Stocks to Invest in Now. While we acknowledge the potential of SVRA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SVRA and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 10 Best Low Volatility Stocks to Buy Now and Starter Stock Portfolio: 12 Safe Stocks to Buy Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
21-05-2025
- Business
- Yahoo
Savara Inc. (SVRA): Analysts See 212% Upside Potential
We recently published an article titled . Savara Inc. (NASDAQ:SVRA) was one of the stocks that was covered in that article. Wall Street analysts believe SVRA has a 212% upside potential over the next 12 months. Close-up of an inhaler, representing the inhalation of the molgramostim product candidate. Savara Inc. (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company dedicated to addressing the unmet needs of patients suffering from rare respiratory diseases. Founded in 1995, Savara is a key player in this niche field through innovative therapeutic development and a commitment to delivering life-changing solutions to patients worldwide. The company focuses on diseases that have limited treatment options, ensuring its research has a significant impact on improving health outcomes. The cornerstone of Savara Inc. (NASDAQ:SVRA) current pipeline is MOLBREEVI, a promising therapeutic designed to treat autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disease characterized by the accumulation of surfactant in the alveoli, impeding gas exchange and leading to respiratory distress. MOLBREEVI is currently undergoing Phase 3 clinical trials and has already demonstrated notable improvements in gas exchange, as well as measurable clinical benefits for patients. Savara is actively pursuing regulatory approval through a rolling Biologics License Application (BLA) submission to the FDA, and it is preparing for a Marketing Authorization Application (MAA) to the European Medicines Agency. These efforts reflect Savara's commitment to bringing MOLBREEVI to market as efficiently as possible. Unlike many biopharmaceutical companies, Savara employs a unique business model that emphasizes outsourcing the majority of its clinical development and manufacturing activities to specialized vendors and consultants. This approach enables the company to operate in a capital-efficient manner, maximizing resources while maintaining the highest standards of quality and innovation. Additionally, Savara's leadership team has extensive experience in navigating the complexities of drug development and commercialization, further strengthening its strategic position in the industry. Financially, Savara Inc. (NASDAQ:SVRA) is in a strong position, with approximately $196 million in cash and short-term investments as of its latest financial report. This robust financial reserve ensures the company's operations remain funded through Q2 2027, providing a solid foundation for advancing its pipeline and achieving its goals. Analysts have expressed optimism about Savara's prospects, citing the company's growing momentum, innovative pipeline, and prudent investment strategy as key drivers of its twelve-month average price target of $9.44, which reflects a substantial upside potential of 212.84%. Overall, Savara Inc. (NASDAQ:SVRA) ranks 13th on our list of 13 Best Multibagger Stocks to Invest in Now. While we acknowledge the potential of SVRA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SVRA and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 10 Best Low Volatility Stocks to Buy Now and Starter Stock Portfolio: 12 Safe Stocks to Buy Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Business Insider
19-05-2025
- Health
- Business Insider
Savara announces new data in two poster presentations at ATS Conference 2025
Savara (SVRA) announced new data in two poster presentations at the ATS International Conference 2025. Data presented were from the Phase 3 IMPALA-2 clinical trial of molgramostim in aPAP and demonstrated that molgramostim reduces surfactant burden and improves health-related quality of life outcomes in patients with aPAP. ATS 2025 Posters: Poster Title: Molgramostim Reduces Surfactant Burden and Number of Whole Lung Lavage Procedures in Patients with Autoimmune Pulmonary Alveolar Proteinosis: Results From the IMPALA-2 Phase 3 Clinical Trial. Summary: Molgramostim reduced surfactant burden as measured by ground-glass opacification scores, a radiological measure of surfactant burden. The mean reduction in GGO score from baseline to Week 24 was greater in the molgramostim group than in the placebo group; Fewer patients in the molgramostim group required rescue whole lung lavages compared with placebo. During the 48-week double-blind treatment period, 6 patients in the molgramostim group underwent a total of 15 WLLs and 11 patients in the placebo group underwent a total of 24 WLLs. Poster Title: The Effects of Molgramostim on Respiratory Health-related Quality of Life and Patient-reported Outcomes in Patients with Autoimmune Pulmonary Alveolar Proteinosis. Summary: Molgramostim showed benefit on measures of health-related quality of life and patients' assessment of breathing problems and physical activity, including changes from baseline in St. George's Respiratory Questionnaire Impact and Symptom scores, the EuroQol 5 Dimensions, 5 Levels, Patient Global Impression of Severity, and Patient Global Impression of Change at Weeks 24 and 48, which were included as exploratory endpoints in the trial; Molgramostim improved respiratory HRQoL as measured by changes from baseline to Week 24 in SGRQ Impact and Symptom scores compared with placebo, and the EQ-5D-5L, a generic HRQoL instrument comprised of a short descriptive system questionnaire that allows patients to rate their health across 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Odds ratios of responses on the EQ-5D-5L numerically favored the molgramostim group on 3 of the 5 dimensions at Weeks 24 and 48; Molgramostim reduced the severity of breathing problems, as assessed by PGIS, at both Weeks 24 and 48. Additionally, more molgramostim patients reported improvements in overall change in daily physical activity level, as measured by more patients assessing themselves as 'Much better' or 'A little better' compared with placebo at Week 24 and Week 48
Yahoo
06-02-2025
- Automotive
- Yahoo
PMH partners with LiveRaceMedia, Sheheen for 2025 live stream
Parella Motorsports Holdings (PMH) has announced changes to its live stream production for the 2025 season, partnering with LiveRaceMedia and lead announcer Ralph Sheheen to bring viewers live coverage of 20 SpeedTour events this season. With two full days of coverage each event weekend, viewers will be able to enjoy racing from the Trans Am Series presented by Pirelli (pictured above), Sportscar Vintage Racing Association (SVRA), Formula Regional Americas Championship, Formula 4 United States Championship, Ligier JS F4 Series, International GT (IGT) and Prototype Sprint Series Association presented by Hankook (PSSA). 'We're thrilled to partner with LiveRaceMedia and Ralph Sheheen to bring the fans at home coverage of SpeedTour events in 2025,' said Kim McCullough, Chief Marketing Officer of PMH. 'Ralph Sheheen has decades of experience as a broadcaster; his expertise and passion for the sport will elevate the coverage of every race. LiveRaceMedia is one of the best in the business, between showing fans the action on the track and personalities behind the helmets, we know they'll do a great job capturing SpeedTour events.' Headquartered in Green Bay, Wis., LiveRaceMedia has covered premiere motorsport events around the world. Utilizing a variety of track, pit lane, drone and on-board cameras, LiveRaceMedia employs the most advanced broadcasting technology to bring fans coverage of the on-track action. 'We're excited to partner with SpeedTour to bring the fans at home coverage of their action-packed events in 2025,' said Brandon Rohde, Owner/CEO of LiveRaceMedia. 'We worked with them a bit last season covering events at Indianapolis Motor Speedway and New Jersey Motorsports Park. With seven owned race series, the energy and excitement during a SpeedTour weekend is off the charts. We're excited to capture that on camera and share it with motorsports fans around the world.' Sheheen has been covering motorsports on national television for nearly 40 years. He has covered everything from Swamp Buggies to Formula 1 and from Supercross to MotoGP. Having worked with major television networks such as CBS, FOX, NBC, ESPN and more, Sheheen will become the voice of SpeedTour TV, covering 20 race weekends from coast to coast. 'I have enjoyed the SpeedTour events as a fan, and now I get the honor of being the voice of the series,' said Sheheen. 'I have a huge passion for all forms of racing and I look forward to adding to the excitement of these action-packed events. I think it is a fantastic weekend of thrilling competition from a wide variety of classes. From the thundering Trans Am machinery, both new and vintage, to a combination of open-wheel classes that are an exciting training ground for the sport's future stars, as well as the captivating SVRA classics which provide a spectacular rolling history of motorsports along with a cacophony of tremendous engine notes, SpeedTour offers something for everyone. It's going to be an awesome season and I can't wait to get started!' SpeedTour TV's 2025 coverage kicks off with the Sebring SpeedTour, Feb. 22-23. Racing from Trans Am, SVRA, PSSA and IGT will be live both days, with the stream available on and the SpeedTour TV YouTube channel. Story originally appeared on Racer
